Find us on:

Research

Disease
Research Type
Reported as
Publication Type
Sort By
Total: 154
Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases.
Research Type Human Reported as Review Date July 01, 2019 Authors A Jfri, IV Litvinov, E Netchiporouk Institution McGill University Disease Darier Disease, Hailey-Hailey
Darier (DD) and Hailey-Hailey (HHD) diseases are both genodermatoses caused by defective calcium transport and homeostasis. DD is caused by a mutation of the ATPA2A gene and HHD by a mutation of the ATP2C1 gene. Clinically, the former is characterized by itchy, painful macerations with red-brownish papules in a seborrheic distribution; the latter manifests with painful blisters that rupture, leaving erosions in intertriginous areas. Treatment options for both conditions are limited and include t...
Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis
Research Type Human Reported as Case Report/Series/Restrospective Study Date June 01, 2019 Authors Albert P. Manudhane, Kory P. Schrom, Harib H. Ezaldein, James A. Armile Institution Brown University Warren Alpert Medical School, University Hospitals Cleveland Medical Center, Case Western Reserve University, Lake Erie College of Osteopathic Medicine Disease Amyopathic Dermatomyositis
Gottron papules, a heliotrope rash, scalp and extremity erythema, pruritus, and fatigue are the characteristic signs and symptoms of amyopathic dermatomyositis (ADM). Amyopathic dermatomyositis is considered a distinct entity from dermatomyositis (DM) because the characteristic muscle weakness and muscle enzyme elevations of DM are absent in ADM. With respects to treatment, ADM treatments have traditionally included topical corticosteroids and/or systemic immunosuppressants and immunomodulators....
Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): a case series.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 16, 2019 Authors C. Riquelme-Mc Loughlin, J. Riera-Monroig, D. Morgado-Carrasco, P. Giavedoni, S. Podlipnik, P. Iranzo, J.M. Mascaró Jr Institution University of Barcelona Disease Hailey-Hailey
University of Barcelona physicians studied the effect of low dose naltrexone (LDN) on 14 patients with Hailey-Hailey disease (HDD), also known as benign chronic pemphigus. The authors suggest that future studies be done to determine if certain genetic profiles are associated with favorable responses to LDN....
Use of low-dose naltrexone in the treatment of severe Hailey-Hailey disease: one case report.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 08, 2019 Authors María Garayar Cantero, Marina Canseco Martín, Ángel Aguado García, Pilar Manchado López Institution Hospital Clínico Universitario de Valladolid Disease Hailey-Hailey
INTRODUCTION: Hailey-Hailey disease (HHD) or chronic benign familial pemphigus is an autosomal dominant genodermatosis with complete penetrance characterized by painful vesicles, erosions and macerated intertriginous skin. CASE REPORT: We present a 66-year-old woman with a personal 35-year history of pruritic recurrent vesicles and erosions in both axillae and inguinal folds. HHD was confirmed by cutaneous biopsy. Past treatments had failed, including topical corticosteroids, antibiotics and ...
Low Dose Naltrexone for Neuropathic Pain Related to an Electrical Burn Injury: A Case Study
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors M. Cowling, M. Poliak-Tunis Institution University of Wisconsin Disease Chronic Pain
A 36- year old male with a past history significant for bipolar disorder, depression, and PTSD presented to UW Pain Clinic for management of ongoing pain related to an electrical burn injury (4.5%) to the left hand and flank sustained in August 2016. He underwent a skin graft for the burn six months later and has experienced difficulties with his pain since. During the consult, the patient described his pain as a burning, tingling sensation over the left flank and hand. He also experiences sharp...
Low-Dose Naltrexone in the Treatment of Fibromyalgia: A Retrospective Analysis
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors Jordan Wulz Institution Ascension Wisconsin Center for Pain Management, Concordia University Wisconsin Disease Fibromyalgia
The first scientific reference of fibromyalgia as a medical disorder occurred in 1981. Since then, pain management experts have continuously debated diagnosis criteria, potential pathologies, and viable treatment options due to the complex nature of the disease. For both patient and clinician, the efficacy of current pharmacologic treatments can be frustrating. The clinical benefit of medications is often modest at best. In fact, the 2016 European League Against Rheumatism (EULAR) guideline for ...
Inexpensive compounding of low dose naltrexone (LDN) with orange juice.
Research Type Human Reported as Opinion Date March 28, 2019 Authors R. Bronfenbrener Institution University of Pennsylvania, Yardley Dermatology Associates
One can compound LDN using commercially available tablets and orange juice. Doing so helps improve the texture and taste over using water. The ratio of medicine to juice is described. It is recommended to keep the mixture in the refrigerator and shake it prior to dispensing. Other juice flavors can be used based on patient preference. Following this procedure, patients can expect to get 3 months of medicine for about $15. Making LDN inexpensively should allow for the expansion of the use of LDN....
Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts.
Research Type Lab (in-vitro) Reported as Clinical Trial Date March 28, 2019 Authors K. Tanaka, H. Kondo, K. Hamamura, A. Togari Institution Aichi-Gakuin University
AIMS: Opioid receptor blockers such as naloxone and naltrexone have been suggested to have a bone mass-increasing effect. However, the mechanisms at play have not been clarified. We examined the effects of naltrexone on osteoblasts and determined the expression of opioid growth factor receptor (OGFR) in osteoblasts. Naltrexone blocks the OGFR and other canonical opioid receptors. Thus, we designed experiments to clarify the effects of naltrexone on bone tissue by examining the physiological role...
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes
Research Type Human Reported as Review Date March 27, 2019 Authors Diana Trofimovitch, Steven J. Baumrucker Institution East Tennessee State University College of Medicine, Ballad Health System Hospice and Palliative Medicine Disease Chronic Pain
Pain can have a devastating effect on the quality of life of patients in palliative medicine. Thus far, majority of research has been centered on opioid-based pain management, with a limited empirical evidence for the use of nonopioid medications in palliative care. However, opioid and nonopioid medications such as nonsteroidal anti-inflammatory drugs have their limitations in the clinical use due to risk of adverse effects, therefore, there is a need for more research to be directed to finding ...
The use of naltrexone in dermatology. Current evidence and future directions.
Research Type Human Reported as Review Date March 18, 2019 Authors Mariusz Sikora, Adriana Rakowska, Małgorzata Olszewska, Lidia Rudnicka Institution Medical University of Warsaw
Naltrexone is a competitive opioid receptor antagonist approved as supportive treatment in alcohol dependence and opioid addiction. In a dose 50-100 mg daily, naltrexone is used off-label in dermatology for the treatment of trichotillomania and different types of pruritus. At a dose as low as 1-5 mg of drug per day, naltrexone demonstrates immunomodulatory action i.e. modulates Toll-like receptors signaling, decreases release of proinflammatory cytokines (tumor necrosis factor, interleukin-6, in...